Category Archives: Regional News

You are here: Home » Category: "Regional News"

Aclaris Therapeutics Receives FDA Approval for ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses (SKs)

ESKATA™ is the First and Only FDA-Approved Topical, Non-invasive Treatment for Raised SKs; Management to Hold Conference Call at 8:00 AM ET Today MALVERN, Pa., Dec. 15, 2017 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ESKATA™ (hydrogen peroxide) topical solution,…

[Read More]

INC Research/inVentiv Health to Present at Upcoming J.P. Morgan Healthcare Conference

RALEIGH, N.C., Dec. 14, 2017 (GLOBE NEWSWIRE) — INC Research/inVentiv Health (Nasdaq:INCR), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco. Mr. Macdonald’s presentation is scheduled for Tuesday, January 9, 2018, at 8:00 a.m….

[Read More]

BioDelivery Sciences Reacquires ONSOLIS® from Collegium Pharmaceutical

RALEIGH, N.C., Dec. 14, 2017 (GLOBE NEWSWIRE) — BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced that it has received the required 90-day notice from Collegium Pharmaceutical, Inc. regarding termination of the license and development agreement for ONSOLIS® (fentanyl buccal soluble film) between BDSI and Collegium.    BDSI and Collegium entered into a license and development agreement…

[Read More]

India Globalization Capital Provides Update on Hyalolex for Alzheimer’s Commercialization Strategy

BETHESDA, Md., Dec. 14, 2017 (GLOBE NEWSWIRE) — India Globalization Capital, Inc. (NYSE American:IGC) today provides an update on corporate initiatives to launch its lead product for Alzheimer’s, Hyalolex, through licensed medical dispensaries in the U.S.  Investors and interested parties are encouraged to visit www.Hyalolex.com for information on Alzheimer’s disease and research data related to…

[Read More]

Strongbridge Biopharma plc Announces New Employment Inducement Awards

DUBLIN, Ireland and TREVOSE, Pa., Dec. 14, 2017 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has approved inducement equity awards to 21 individuals who have recently become, or are expected to…

[Read More]

Amalgam Rx Partners with UCB on BEYOND™, a Digital Health Solution for Patients with Psoriasis and Psoriatic Arthritis

WILMINGTON, Del., Dec. 13, 2017 (GLOBE NEWSWIRE) — Allay Rx, a subsidiary of Amalgam Rx, Inc., a leading digital therapeutics company, announced today a partnership on a comprehensive behavioral and patient support program, BEYOND, for patients living with psoriasis and psoriatic arthritis. BEYOND is a mobile application and provides patients with a trusted source of…

[Read More]

Strongbridge Biopharma plc Added to the NASDAQ Biotech Index

DUBLIN, Ireland and TREVOSE, Pa., Dec. 13, 2017 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, announced today that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:NBI), which will become effective prior…

[Read More]

Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index

RADNOR, Pa., Dec. 13, 2017 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that it has been selected for addition to the NASDAQ Biotechnology Index®, which will become effective prior to the open of U.S. markets…

[Read More]